Is Eloxx Pharmaceuticals going out of business?

ELOXX PHARMACEUTICALS, INC. (ELOX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ELOXX PHARMACEUTICALS, INC. (ELOX) scores 18 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (14427.0% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Stable

42+ mo of estimated runway from 2026-06-30, based on $62.0M of cash and short-term investments against $15.0M of annual burn. Adjusted shares outstanding increased 14427.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

4.5% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (14427.0% YoY) and the capital-structure risk is penalized.
• ROIC: 43.67%
• Interest coverage: -11.0x
• Debt / Equity: No financial debt (debt-free)
• Return on Assets: -9.46%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-11.

Price as of 2026-08-22.